NCT05314023View on ClinicalTrials.gov

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,590

Participants

Timeline

Start Date

May 7, 2022

Primary Completion Date

February 19, 2029

Study Completion Date

February 19, 2029

Conditions
Genital Warts
Interventions
BIOLOGICAL

9vHPV vaccine

A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.

Trial Locations (5)

417000

Loudi Public Health Hospital (Loudi Occupational Disease Prevention And Treatment Hospital) ( Site 0, Louxing District

545200

Liucheng County Centers for Disease Control and Prevention ( Site 0005), Liuzhou

545400

Center for Disease Control and Prevention of Rong An ( Site 0006), Liuzhou

621100

Santai County Center for Disease Control and Prevention ( Site 0001), Mianyang

638399

Yuechi Disease Prevention and Control Center ( Site 0002), Guang’an

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY